Cart
sales@molnova.com
CORM-3
CAS No. 475473-26-8
CORM-3( —— )
Catalog No. M14582 CAS No. 475473-26-8
CORM-3 is a water-soluble carbon monoxide-releasing molecule with anti-inflammatory and cardioprotective activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 50 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 48 | In Stock |
|
| 25MG | 80 | In Stock |
|
| 50MG | 114 | In Stock |
|
| 100MG | 169 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 425 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCORM-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionCORM-3 is a water-soluble carbon monoxide-releasing molecule with anti-inflammatory and cardioprotective activity.
-
DescriptionCORM-3 is a water-soluble carbon monoxide-releasing molecule with anti-inflammatory and cardioprotective activity.
-
In VitroCORM-3 suppresses caspase-1 activation and the secretion of interleukin (IL)-1β and IL-18 in macrophages in response to lipopolysaccharide (LPS) and ATP. CORM-3 inhibits the oligomerization of the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which is required for NLRP3-dependent caspase-1 activation.
-
In VivoCORM-3 (4 mg/kg, ip) reduces NLRP3 inflammasome activation and inhibits hyperglycemia-induced inflammation in mice. Animal Model:WT mice (C57BL/6J male, 8e10 weeks old).Dosage:4 mg/kg.Administration:IP for 3 h before i.p. injection of E. coli LPS (10 mg/kg), and IP injection after 7-day-treatment of S0130.Result:Resulted in significantly lower plasma levels of IL-1β and IL-18 in response to LPS challenge in vivo in WT mice relative to that in vehicle-treated control mice, whereas TNF-a levels were unchanged.Had lower expression of cleaved caspase-1 and cleaved IL-1b in response to ATP and nigericin, relative to vehicle control, whereas the expression of procaspase-1 and pro-IL-1β expression was unchanged.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number475473-26-8
-
Formula Weight294.61
-
Molecular FormulaC5H4ClNO5Ru
-
Purity>98% (HPLC)
-
SolubilityDMSO:38 mg/mL (128.98 mM); Ethanol:<1 mg/mL (<1 mM); Water:<1 mg/mL (<1 mM)
-
SMILES[*].Cl[Ru]1(NCC(=O)O1)(C=O)(C=O)C=O |$;_R0;;;;;;;;;;;;;$|
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
GR 64349
Potent and selective tachykinin NK2 receptor agonist (EC50 = 3.7 nM in rat colon). Displays > 1000- and > 300-fold selectivity over NK1 and NK3 receptors respectively. Active in vivo.
-
Ladiratuzumab
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.
-
HIF-1 alpha 556-574
HIF-1 alpha (556-574) is a hypoxia-inducible factor-1 19-mer fragment. HIF-1 functions as master regulator of response to oxygen homeostasis. Hypoxia-induced gene expression is initiated when HIF-1subunit is stabilized in response to a lack of oxygen. This part of HIF-1 binds to the von Hippel-Lindau factor (VHL) an E3 ubiquitin ligase, and the proline 564 is absolutely vital to the binding process.
